Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Year: 2015
Type: article
Abstract: To the editor:
Understanding of the tumor microenvironment has led to the development of novel agents for lymphoma, although few studies have combined these as a therapeutic strategy. We report unacceptable toxicity from such a biological triplet. Patients were treated in a multiarm phase 1 study
Source: Blood
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2121039860